Dr. Debu Tripathy discusses recent research on the use of circulating tumor DNA in metastatic breast cancer care. Circulating tumor DNA, also referred to as ctDNA, are small pieces of DNA that are ...
Low baseline ctDNA levels in advanced breast cancer patients predict better response to targeted therapy and longer ...
Data confirms Versamune® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025 Versamune® HPV + CRT ...
We conducted a systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC to evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection and ...
Large Language Models in Population Oncology: A Contemporary Review on the Use of Large Language Models to Support Data Collection, Aggregation, and Analysis in Cancer Care and Research This work ...
This study is led by Prof. Luo Huiyan and Prof. Xu Ruihua (Department of Medical Oncology, Sun Yat Sen University Cancer Center). Colorectal adenomas (CRAs) represent precancerous lesions that precede ...
Circulating tumour DNA (ctDNA) monitoring identified patients with muscle-invasive bladder cancer who showed significantly longer disease-free survival and overall survival when treated with adjuvant ...
A study led by scientists at NYU Langone Health and its Perlmutter Cancer Center has shown that monitoring blood levels of DNA fragments shed by dying tumor cells may accurately predict skin cancer ...
A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...
DNA levels at baseline and during treatment predict response and progression free survival in advanced breast cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results